Chikungunya – Pipeline Review, 2024

Chikungunya is a viral disease caused due to bite of an infected mosquito. Symptoms of chikungunya are commonly identified after 3-7 days after a mosquito bite. Symptoms observed in patients with chikungunya are high fever, rashes, headache, muscle pain, joint pain, nausea, and fatigue. Chikungunya is diagnosed by a serological test. The signs of chikungunya are very similar to dengue and thus can be misdiagnosed.

Currently, there are no vaccine or drugs available to treat chikungunya. Treatment has been provided for relieving the symptoms rather than treating the cause. Over the counter (OTC) drugs such as ibuprofen, naproxen, acetaminophen helps to reduce the fever and joint pain and increase in fluid intake is recommended to the patients to prevent dehydration.

Research Institutes and pharmaceutical companies are focusing on studying and developing new methods for the treatment of chikungunya. For instance; MV-CHIK low dose is being studied by Themis Bioscience GmbH, is currently in phase 2 of clinical trial for the study to evaluate the immunogenicity, safety, and tolerability in patients with chikungunya viral infection. National Institute of Allergy and Infectious Diseases (NIAID) is conducting a study on VRC-CHKVLP059-00-VP to evaluate the immunogenicity and safety in healthy adults as chikungunya vaccine. It is currently in phase 2 of clinical trials.

Currently, more than 50% of the pipeline candidates for chikungunya are in phase 1 and phase 2 of clinical trials. Among these majority of studies is being sponsored by research institutes.

REPORT DESCRIPTION

The report on ‘Chikungunya – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for chikungunya. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for chikungunya.

The report on ‘Chikungunya – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for chikungunya


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for chikungunya


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary